I'm afraid you have revealed your ignorance of oncology with these posts, so I will try and keep this quite simple.
1. This patient had a prior allogeneic transplant which failed. 2. The patient relapsed and presented with high risk MDS with circulating blasts and high tumor burden - I'll save you the google search and tell you that means they are extremely ill with a very poor prognosis. 3. Stable disease and then complete response was induced by CHM CORE-NK treatment. 4. The patient then received a consolidation allogeneic transplant.
Consolidation therapy is only given following successful induction therapy with the aim of remission maintenance. It cannot, therefore, be the cause of the complete response and in fact would never even be done in the absence of successful induction by CORE-NK.
CHM Price at posting:
15.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)